Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of Nexvax2 in Patients With Celiac Disease
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 19 May 2017
Price :
$35
*
At a glance
- Drugs HLA DQ2 peptide vaccine (Primary)
- Indications Coeliac disease
- Focus Adverse reactions
- Sponsors ImmusanT
- 12 May 2017 Results from this and other trial (see profile 239677) published in an ImmusanT Media Release
- 11 May 2017 Results from this and other trial (see profile 239677) published in The Lancet Gastroenterology and Hepatology
- 22 Mar 2017 Status changed to completed.